GSK shares dive as weaker sales and mounting costs unnerve investors
GlaxoSmithKline’s share price dropped sharply after the company posted lower-than-expected profits, citing reduced vaccine sales and rising operating expenses. The outlook was further dampened by the impending loss of patent protection for its leading HIV medication, which could erode future revenue. Analysts said the combination of weaker demand and cost pressures unsettled investors. The news added to broader market concerns about the sector’s growth prospects.